Federal award (DELIVERY ORDER, fiscal year 2022)
Recipient: THE INSTITUTE FOR CANCER RESEARCH
Awarding agency: Department of Health and Human Services / National Institutes of Health
Funding agency: Department of Health and Human Services / National Institutes of Health
Period of performance: 2018-07-25 to 2023-07-24
Current total value of award: $884185.34
Description: PRECLINICAL PREVENT CANCER PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS  TO TITLE: NOVEL NON-COX INHIBITORY SULINDAC DERIVATIVE FOR COLORECTAL CANCER CHEMOPREVENTION WITH SELECTIVE PDE-10 AND WNT/B-CATENIN INHIBITORY ACTIVITY